You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies
SBC: ISOPLEXIS CORPORATION Topic: 102While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Anti-Fibrotic Therapy for Scleroderma/SSc
SBC: Angion Biomedica Corp. Topic: NIAMSDESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, blood vessels, GI and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,000 to 900,000 people in th ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Whole-brain fluorescence and brightfield imaging at single-cell level
SBC: DMetrix, Inc Topic: NIADESCRIPTION (provided by applicant): The goal of this project is to develop an open and flexible imaging platform capable of rapid, 0.5- 5 m pixel resolution image capture of large-area histology sections (up to 125 mm by 175 mm), in brightfield and by epi-fluorescence optical sectioning. The project involves state-of-the- art instrumentation development coupled with application programming inter ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper
SBC: Pulmokine, Inc. Topic: NHLBIDESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with high morbidity and mortality. Signaling through the PDGFR leads to smooth muscle cell proliferation ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
SmartStop: Programmable Transdermal Nicotine Replacement Therapy
SBC: CHRONO THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): According to the Centers for Disease Control and Prevention, cigarette smoking causes the vast majority of lung cancers and over 400,000 deaths annually with a total monetary cost exceeding 190 billion. While the majority of the 45+ million US smokers want to quit, a small fraction of this number actually succeeds. The most popular smoking cessation products u ...
SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Isochoric Pressure Based Preservation of Cells, Tissues and Organs
SBC: SYLVATICA BIOTECH INC Topic: NIAIDPROJECT SUMMARY/ ABSTRACT There is wide recognition within the transplant and broader biomedical communities, as well as government funding agencies, that extended and improved preservation of biological materials is needed for a huge range of endeavors in biomedicine, medical research and drug discovery, organ and tissue transplantation, cell-based therapies, fertility and regenerative medicine, ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD
SBC: OLIGOMERIX INC Topic: NIATITLE: GMP Synthesis of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD PROJECT SUMMARY - SBIR Funding Opportunity: NIA PAS-18-187, andquot;Advancing Research on Alzheimerandapos;s Disease (AD) andamp; AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)andquot; The long-term goal of this program is to develop a disease-modifying, small molecule drug for Alzheimer’s dis ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Therapeutic for Liver Fibrosis
SBC: Angion Biomedica Corp. Topic: NIAAADESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to allevate the unde ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma
SBC: Curebiotech, Inc. Topic: 102PROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer, causing a large majority of skin-cancer related deaths worldwide. The combination of anti-PD-1 and anti-CTLA-4 is FDA approved for metastatic melanoma and shows better efficacy than any single agent alone. Unfortunately, the incidence of high-gr ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
SBC: OLIGOMERIX INC Topic: NIAThe long-term goal of this program is to develop a disease-modifying, small molecule drug for Alzheimer’s disease (AD) and AD related dementias (ADRD) with tau pathology. There is a critical unmet need for a disease-modifying drug (DMD) for AD. Chronic treatment strategies require safe, effective, and economically feasible approaches such as small molecule drugs. This program is progressing to f ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health